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Abstract: Background: Mucopolysaccharidosis type I-Hurler (MPS1-H) is a severe genetic lysosomal
storage disorder due to loss-of-function mutations in the IDUA gene. The subsequent complete
deficiency of alpha l-iduronidase enzyme is directly responsible of a progressive accumulation of
glycosaminoglycans (GAG) in lysosomes which affects the functions of many tissues. Consequently,
MPS1 is characterized by systemic symptoms (multiorgan dysfunction) including respiratory
and cardiac dysfunctions, skeletal abnormalities and early fatal neurodegeneration. Methods:
To understand mechanisms underlying MPS1 neuropathology, we generated induced pluripotent
stem cells (iPSC) from a MPS1-H patient with loss-of-function mutations in both IDUA alleles.
To avoid variability due to different genetic background of iPSC, we established an isogenic control
iPSC line by rescuing IDUA expression by a lentivectoral approach. Results: Marked differences
between MPS1-H and IDUA-corrected isogenic controls were observed upon neural differentiation.
A scratch assay revealed a strong migration defect of MPS1-H cells. Also, there was a massive impact
of IDUA deficiency on gene expression (340 genes with an FDR < 0.05). Conclusions: Our results
demonstrate a hitherto unknown connection between lysosomal degradation, gene expression and
neural motility, which might account at least in part for the phenotype of MPS1-H patients.
Keywords: induced pluripotent stem cells; neuronal differentiation; disease modelling;
mucopolysaccharidosis I; neural migration; neurite outgrowth
1. Introduction
Mucopolysaccharidosis type I-Hurler (MPS1-H) is a rare inherited metabolic disorder caused by
loss-of-function mutations in the IDUA gene leading to the complete deficiency of alpha-L-iduronidase,
the enzyme involved in the degradation of glycosaminoglycans (GAGs) [1,2]. The progressive
intralysosomal accumulation of dermatan sulfate (DS) and heparane sulfate (HS) in tissues is directly
linked to multiorgan dysfunction [2]. So, the mucopolysaccharidosis type I-Hurler (MPS1-H),
which is the most prevalent phenotype and the most severe form of MPS1, is characterized by
critical musculoskeletal alterations, cardiovascular, respiratory affections and serious neurological
dysfunctions [3–6]. Despite this broad phenotypic spectrum [2], the progression of MPS1-H pathological
process is insufficiently advanced at birth to detect any phenotypic alteration. Indeed, children with
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Hurler’s syndrome (MPS1-H) do not develop specific clinical features such as coarse facies traits or
hernias until 3–6 months of age [7,8]. Likewise, cognitive abnormalities are rarely detected during
the first year of life [2]. This delay of pathological manifestations is problematic as the progression
of MPS1-H is rapid and death usually occurs prematurely within the first decade of age if left
untreated [9,10]. The success of therapeutic treatments, which is essentially based on hematopoietic
stem cells transplantation (HSCT) [11] is often correlated to an early diagnostic [12]. If MPS1-H patients
are treated before the progressive decline, usually starting around 2 years-old [13], their lifespan can
be prolonged, irreversible neurological damages can be limited and consequently their intelligence
quotient (IQ) score stabilized [6,14,15].
Although these neurological defects are also detected in MPS2, MPS3 and in some case of other
subtype of MPS1, they are more varied and severe in MPS1-H [16]. Thus, MPS1-H patients can
present sleeping disorders, behavioral problems, limited language, hearing loss [2] and cognitive
impairment [2,3,5,6,16]. Although some of these disorders are directly derived from developmental
abnormalities such as the limited language which may resulted from both hearing loss and enlargement
of the tongue [2,17], the causes of other neurological symptoms remain poorly understood.
Some studies, carried out using fibroblasts [18] or iPSCs [19], isolated or derived from
MPS3 patients, have highlighted alterations of cell migration and neuritogenesis. These defects,
also observed in MPS3 mice [20], would result from HS proteoglycan accumulation which would
disrupt normal brain development. Moreover, the use and the characterization of different mouse
models of MPS1 and MPS3 revealed a secondary accumulation of gangliosides (GM2 and GM3) in
the central nervous system (CNS) of MPS mice [21–23]. Since this ganglioside storage has also been
observed in the brains of patients affected by different forms of MPS [24,25], other studies explored the
probable effects of excessive gangliosides in the pathological process of MPS1 [26] and hypothesized
its possible involvement in the onset of hyperactive behavior [27,28], and sleeping disorders due to
alteration of circadian rhythms [29]. Nevertheless, other unknown neuropathological mechanisms
must be implicated [23].
In this study, we took advantage of the potential of induced pluripotent stem cells (iPSC),
derived from a MPS1-H child [30], to reproduce, in vitro, the different steps observed during neural
development and to identify any cellular and molecular defects responsible of neuropathological
manifestation. To counteract the major cause of transcriptional variation resulting from the genetic
background difference between individual lines [31], we generated an isogenic control iPSC line,
constitutively expressing the alpha-l-iduronidase. Both MPS1-H and rescue MPS1-H (rMPS1-H)
iPSCs were differentiated into neuronal lineage. Analysis of RNA sequencing (RNA-seq), which was
performed on 3-weeks old neurospheres derived from these iPSCs lines, allowed the identification of
clusters of genes pointing towards migration defects and neuroanatomical defects. The alteration of
migration was validated, in vitro, by the performance of a scratch test on neural stem/progenitor cells
(NSCs) derived from MPS1-H iPSCs. In addition, maturation of these MPS1-H NSCs highlighted a
defective neurite outgrowth. All molecular and cellular alterations identified in MPS1-H neural cells
may explain some of neuropathological features described in MPS1-H patients.
2. Materials and Methods
2.1. Construction of Plasmid and Lentiviral Vector
IDUA cDNA ORF expression clone NM_000203.4 (GeneCopoeia, Rockville, MD, USA) was cloned in
GATEWAY™EntryplasmidbyPCR(Herculase IIFusionDNApolymerase, Agilent, SantaClara, CA,USA)by
using Fwd: 5′-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACC ATGCGTCCCCTGCGCCCCCG-3′
and Rev: 5′-GGGGACCACTTTGTACAAGAAAGCTGGGT TCATGGATTGCCCGGGGATGGGGG-3′
primers. The final lentivector plasmid was assembled by a GATEWAY™ LR Clonase™ II (ThermoFisher,
Reinach, Switzerland), mediated recombination of a pENTR plasmid containing the human UBI and a
lentivector destination cassette containing an additional transcription unit encoding for blasticidin
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resistance gene upon human PGK promoter. Final lentivector was produced by transient transfection of
HEK 293T cells with the generated lentivector plasmid pCWX-UBI-IDUA-PGK-BSD, the pCAG-VSVG
envelope plasmid and the psPAX2 plasmid encoding gag/pol, following the CaPO4 method [32].
2.2. Lentiviral Vector Transduction and Rescue
α-l-Iduronidase enzyme (IDUAα) activity have been both restored in MPS1-H fibroblasts, MPS1-H
iPSCs and MPS1-H iPSCs-derived NSCs by using UBI-IDUA-PGK-BSD lentivector. One day before the
transduction, MPS1-H cells were seeded at 33% of confluency on 6 well plates. Cells were transduced
using a MOI of 5. Cells were cultured for 5 days before starting blasticidin selection. 5 µg/mL of
blasticidin was added to the medium during 7 days. Culture medium was changed daily.
2.3. IDUA Activity Measurement Assay
The IDUAα activity assay was performed by fluorimetric determination using 4MU α-L-iduronide
on cell lysate by [33] modified protocol. One µg of protein interacted with 7 µg of 4MU α L-iduronide
(Glycosynth, Cheshire, UK), 2.5 µg of saccharonolactone (Sigma-Aldrich, Buchs, Switzerland) at
37 ◦C, 5% CO2 during 20 min on a shaking platform. Reaction stop is given by pH10 glycine buffer
(Sigma-Aldrich, Buchs, Switzerland). Measurement was made by PARADIGM reader (Molecular
Devices, Sunnyvale, CA, USA) at λex = 355 nm, λem = 465 nm. IDUAαwas calculated using fluorescence
extrapolating from 50 nM 4MU standard solution (Sigma-Aldrich, Buchs, Switzerland).
2.4. Establishment and Characterization of MPS1-H iPSC Line
The MPS1-H iPSC line was generated from the reprogramming of dermal fibroblasts, isolated
from a skin biopsy of 2-year-old male MPS1-H child [30]. The loss-of-function of IDUAα have
been associated to the presence of two distinct mutations distributed on the two alleles of the IDUA
gene: NM_000203.5(IDUA):c.1073_1093del (p.His358_Thr364del) and NM_000203.4(IDUA):c.1205 G>A
(p.Trp402Ter). All details concerning reprogramming, cell culture maintenance and characterization of
the line have been reported in a previous study [30]. The isogenic control iPSC line, resulting from the
transduction of MPS1-H iPSC line with a lentivector allowing the expression of normal IDUA gene,
have been characterized in similar experimental conditions. The tree clones S1, S2 and S4 of MPS1-H
iPSCs were rescued. The clone S3 was not rescued since its genome integrity had not been validated by
a previous comparative genomic hybridization (CGH) array.
2.5. hiPSC-Derived NSCs
hiPS clones were differentiated in vitro toward neuronal lineage using a monolayer based
differentiation protocol and DUAL SMAD inhibition [34]. Cells were cultured for 15 days, passaged on
Matrigel-coated flasks at 5.5 × 105 cells/cm2.
2.6. NSCs Culture
Cells (5.5 × 105/cm2) were plated on pre-coated poly-L-ornithine/laminin dishes (2 µg/cm2)
in Neurobasal medium supplemented with 2 mM L-glutamine, B27 supplement 0.2% final,
NEAA (Life Technologies, Europe BV, Zug, Switzerland). 10 ng/mL of fibroblast growth factor 2 (FGF2;
R&D systems) and epidermal growth factor (EGF; Life Technologies Europe BV, Zug, Switzerland) was
added to the medium to promote proliferation. Medium change occurred every other day.
2.7. NSC Differentiation
Differentiation was initiated when NSCs reached 80% confluency. Both FGF2 and EGF were
then removed from medium. Medium change was performed every 2–3 days. On day 10, cells were
detached with accutase® (Invitrogen, Basel, Switzerland) for 5 min at 37 ◦C, before to be plated
on poly-L-ornithine/laminin coverslips at 158,000 cells/cm2. Cells were cultured in B27 neurobasal
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medium supplemented with 20 ng/mL of BDNF and GDNF (R&D Systems, Minneapolis, MN, USA)
for additional 11 days. Only half of the medium was gently changed every 3–4 days.
2.8. Neurospheres Differentiation Protocol
MPS1-H iPSCs and rMPS1-H iPSCs were plated on Matrigel® coated P150 flasks as described above.
When iPSCs colonies reached 80% confluency, neural induction was promoted by switching the medium
with X-vivo 10 medium (Lonza, Basel, Switzerland) supplemented with 0.5 µM of LDN193189 and
10µM of SB431542. 10µM of Y-27632 (Axon Medchem BV, Groningen, The Netherlands) was also added
to the medium for 24 h. The day after (day 1), iPSCs were dissociated enzymatically with Accutase®
(Invitrogen) for 5 min at 37 ◦C and the resulting single-cell suspension was evenly distributed to
1000 cells/microwell of AggreWell™400 plates (Stemcell Technologies, Grenoble, France). At day
2, resulted uniform spheres were collected and were cultured in rotation (60 rpm, orbital shaker;
Major Science, Saratoga, CA, USA), in uncoated six-well plates, to prevent spheres sticking together.
Half of medium was then changed every 2 days following a strict schedule. At day 3, medium was
substituted with B27 medium containing 0.5% BSA, and supplemented with LDN 0.5 µM, SB431542
10 µM. At day 8, SB431542 was removed from the medium while LDN was removed from day 9.
From day 9, B27 neurobasal medium with 0.5% BSA was supplemented with 10 ng/mL of BDNF and
GDNF, 200 µM of ascorbic acid and 1 µM of db-AMPc (Sigma-Aldrich, Buchs, Switzerland). At day 21,
the neurospheres were analyzed.
2.9. Immunofluorescent Analysis
Coverslips were washed twice with HBSS+ CaCl2, MgCl2 (Gibco by Thermo Fisher Scientific,
Waltham, MA, USA) and fixed with 3% paraformaldehyde (PFA) for 10 min at room temperature (RT).
Permeabilization and antigen quenching was performed by incubating cells for 30 min at RT in blocking
solution constituted by PBS containing 0.1% Triton X-100 and 3% BSA. Cells were then incubated
overnight at 4 ◦C with primary antibodies: Mouse-anti-human MAP2 (Calbiochem by Sigma-Aldrich,
Buchs, Switzerland) 1:500; Mouse-anti-human Ki-67 (Merck Millipore, Schaffhausen, Switzerland) 1:100;
Mouse-anti-human LAMP-1 (H4A3, BD Pharmingen, San Diego, CA, USA) 1:500. Secondary antibodies
were incubated for 1 h at RT. Hoechst staining was performed during incubation of secondary antibody
at 5 µg/mL. Slides were mounted by FluorSave reagent (Calbiochem, EMD-Millipore, Schaffhausen,
Switzerland). Images were captured with an LSM-800 Airyscan (Carl Zeiss AG, Felbach, Switzerland)
microscope. Image acquisition was performed using ZEN software. Quantification and image
processing were performed using MetaMorph and/or ImageJ. Neurite area and length was measured
by ad hoc MathLab journal. Quality checks were performed manually, to ensure that artefacts did not
interfere with measurements.
2.10. Scratch Test
Undifferentiated iPSCs-derived NSCs were seeded onto poly-L-ornithine/laminin pre-coated
96-well plate at a density of 6.25 × 105 cells/cm2. The day after, the scratch was performed using a
P200 pipette tip and NSCs medium was replaced. Plates were incubated at 37 ◦C, 5% CO2 and checked
by ImageXpress widefield high-content analysis system every 12 h until the two migration fronts of
the “scratch” met (48 h post-scratch). Scratch surface calculation was ensued by ImageJ software.
2.11. RNA Sequencing
RNA-seq was performed using triplicate of 3-week-old neurospheres derived from both MPS1-H
iPSCs and rMPS1-H iPSCs. Total RNA was extracted according to the RNeasy Micro kit protocol
(Qiagen, Hombrechtikon, Switzerland). RNA concentrations were measured by Qubit (Invitrogen) and
their quality were validated by using the Bioanalyzer 2100 (Agilent) according to the manufacturer’s
protocol. Stranded cDNA libraries resulted from mRNA by using Illumina TruSeq RNA library
prep kit v2. 100 bp single-paired strands. High throughput sequencing was performed using HiSeq
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4000 (Illumina) which resulted in 30 million copies per sample output on average (38–47 million).
The sequencing quality control was done with FastQC v.0.11.5. The reads were mapped with the TopHat
v.2.0.11 software to the UCSC hg38 human reference. Biological quality control and summarization
were done with the PicardTools v.1.141. The table of counts with the number of reads mapping to each
gene feature of UCSC mm10 was prepared with HTSeq v0.6p1 (htseq-count). Differential expression
analysis was performed in R using the edgeR v. 3.14.0 package [35]. The p-value was corrected for
multiple testing error using FDR (false discovery rate) with the Benjamini-Hochberg (BH) method.
Genes with a p-value < 0.05 were considered differentially expressed.
3. Results
3.1. Restoration of IDUAα Activity of MPS1-H Cells Infected with UBI-IDUA-PGK-BSD Lentivector
The ability of the lentivector to rescue α-l-iduronidase enzyme (IDUAα) was first validated on
MPS1-H patient’s fibroblasts which were used to generate the MPS1-H iPSCs line described in our
previous work by Lito et al., [30]. The UBI-IDUA-PGK-BSD lentivector allowed a constitutive expression
of α-L-iduronidase enzyme (IDUAα) since IDUA is upon ubiquitin (UBI) promotor. An additional
transcription unit encoding for blasticidin resistance gene upon human PGK promoter allowed the
selection of transduced fibroblasts (Figure 1A).
3.1.1. IDUAα Activity of rMPS1 Fibroblasts
The rescue MPS1-H (rMPS1-H) fibroblasts was first validated by measuring the activity of
α-L-iduronidase enzyme (IDUAα). While MPS1-H fibroblasts exhibited no activity of IDUAα
(0.01 ± 0.02 nmol/mg/min), fluorimetric assay revealed an activity of IDUAα (2.24 ± 0.07 nmol/mg/min)
similar to the one observed in control fibroblasts (2.05 ± 0.08 nmol/mg/min) (Figure 1B). Secondly,
we checked the functional impact of IDUAα activity on lysosome storage defects, and more particularly
on lysosome-associated membrane protein 1 (LAMP1) accumulation. While LAMP1 immunostaining
revealed swollen lysosomes in MPS1-H fibroblasts, lysosomes of rMPS1-H fibroblasts were less affected
and are more closely related to normal foreskin fibroblasts (Figure 1C).
3.1.2. IDUAα Activity of rMPS1-H iPSCs
As with fibroblasts, IDUAα activity was restored by the transduction of the three clones (S1,
S2 and S4) of MPS1-H iPSCs, with the UBI-IDUA-PGK-BSD lentivector. While all MPS1-H iPSC clones
were devoid of IDUAα activity, the fluorimetric 4-MU-iduronide assay revealed a significant activity of
IDUAα in the three rescue clones: 2.71 ± 0.32; 5.17 ± 1.21; 3.54 ± 0.94 nmol/mg/min for S1R, S2R, S4R,
respectively (Figure 1D). The higher IDUAα activity in rescued clones of MPS1-H iPSCs compared
to the one determined in an unrelated wild type control iPSC line (2.51 ± 0.05) must result from the
constitutive expression of IDUA, which is upon UBI promotor.
3.1.3. IDUAα Activity of rMPS1-H iPSCs-Derived NSCs
Based on the late onset of pathological displays, and more particularly to neuropathological
defects, due to the progressive accumulation of glycosaminoglycans (GAG) in lysosomes, we first
performed the rescue of MPS1-H iPSCs after their differentiation into neural stem/progenitor cells
(NSCs), meaning once they acquired an immature neural phenotype. The transduction of MPS1-H
iPSC-derived NSCs restored the activity of IDUAα in the three clones: 3.48 ± 0.07; 9.26 ± 1.96;
1.90 ± 0.60 nmol/mg/min for S1R, S2R, S4R respectively (Figure 1E) while IDUAα activity is not
detected in MPS1-H iPSCs-derived NSCs.
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Figure 1. Validation of IDUA rescuing lentivector. (A) Schematic representation of the lentiviral vector.
(B) Iduronidase activity (IDUAα) and (C) LAMP1 expression in MPS1-H fibroblasts, MPS1-H rescued
fibroblasts and normal human forskin fibroblasts (HFF). (D) Iduronidase activity (IDUAα) in the three
MPS1-H (S1–S4) and rMPS1-H iPSCs and (E) iPSCs-derived NSCs clones (S1R–S4R). Data are shown as
mean ± SEM and were analyzed by independent samples t-test. * p < 0.05; ** p < 0.01.
3.2. Characterization of Rescue rMPS1-H iPSCs
In order to minimize any variation resulting from different genetic background between iPSCs
control lines, we generated an isogenic control line by rescuing the functionality of α-L-iduronidase
enzyme (IDUAα) in three clones of MPS1-H iPSCs (S1, S2 and S4). The generated rMPS1-H iPSCs
clones (S1R, S2R and S4R), resulting from the blasticidin selection of MPS1-H iPSCs transduced with
UBI-IDUA-PGK-BSD lentivector were characterized similarly to MPS1-H iPSCs (S4) [30]. Briefly,
rMPS1-H iPSCs presented all specificities of pluripotent stem cells. Cells were tightly packed in colonies
and displayed large nucleoli (Figure 2A). FACS analysis (Figure 2B) and immunofluorescence staining
(Figure 2C) revealed a high expression of the pluripotency transcription factors OCT4, NANOG and
SOX2. Finally, the pluripotency of cells was not affected by the transduction of the lentivector since
their spontaneous differentiation, in vitro, in the form of embryoid bodies (EBs) was oriented toward
the three germ layers. Indeed, after 24 days, AFP, FOXA2 and TUBB3 immunostaining respectively
revealed the presence of endoderm, mesoderm and ectoderm germ layers (Figure 2D).
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Figure 2. Characterization of rescued MPS1-H iPSC line. (A) Rescued MPS1-H iPSC line exhibits
morphological aspects of pluripotent stem cells. (B) FACS analysis and (C) immunofluorescence
staining confirm the expression of pluripotent markers NANOG, SOX2 and OCT4. Nuclei was
counterstained with Hoechst. (D) Validation of the differentiation potential of rMPS1-H iPSC line by
immunofluorescence staining of spontaneously differentiated embryoid bodies into the three germ
layers: endoderm (AFP), mesoderm (FOXA2), and ectoderm (TUBB3). Nuclei was counterstained with
Hoechst. All scale bars = 50 µm.
3.3. IDUA Lentiviral Rescue of MPS1-H NSCs Ameliorates Migration In Vitro
Neuronal migration occurring during the development of CNS development is a fundamental
process leading to severe neurological defects if altered [36]. In order to investigate the functional impact
of iduronidase deficiency on the capacity of migration of neural MPS1-H cells, we performed a classic
scratch assay using the three clones of MPS1-H iPSC differentiated in NSCs and their corresponding
rescued clones (Figure 3A). At 48 h post-scratch, overall covered surface by migrating neural precursors
was 1.11 ± 0.13; 1.19 ± 0.32; 1.12 ± 0.16 mm2 with S1, S2 and S4 clones respectively versus 1.99 ± 0.13;
1.37 ± 0.22; 1.37 ± 0.19 mm2 with the rescued group (Figure 3B). Thus, NSCs displaying a functional
activity of IDUAα migrated significantly more (1.53 ± 0.34 mm2) than NSCs devoid of IDUAα activity
(1.15 ± 0.23 mm2) (Figure 3C). This difference in capacity of migration and motility of rescued MPS1-H
NSCs compared to MPS1-H NSCs was well illustrated in Video S1.
In parallel, the proliferative capacity of the cells was also assessed during the 3 weeks of NSCs
differentiation. As expected, the maturation process was marked by sharp decline in cell proliferation.
Indeed, proliferative Ki67 positive cells declined over time from 80% in immature NSCs to less than
15% in differentiated NSCs for both MPS1-H iPSCs-derived NSCs (84.6 ± 6.3% to 10.2 ± 3.9%) and
their rescued counterparts (77.6 ± 3% to 11 ± 2.7%) (Data not shown). Thus, cell proliferation is not
affected by the mutation of IDUA.
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Figure 3. Migration impairment of undifferentiated MPS1-H iPSCs-derived NSCs. (A) Acquisitions
of MPS1-H and rescued MPS1-H iPSCs-derived NSCs cultures immediately after scratch application
(t = 0) and 48 h later. The red frame shows scratch boundaries. (B) Graphic showing the total migration
surface over 48 h of different all clones of MPS1-H and rescued MPS1-H iPSCs-derived NSCs. Data are
shown as mean ± SEM and were analyzed by independent samples t-test. ** p < 0.01; **** p < 0.001,
n = 3. (C) Pooled results calculated for MPS1-H iPSCs-derived NSCs vs. rescued ones. Data are shown
as mean ± SEM and were analyzed by Welch t-test with Moulton correction, dF = 3.4; t = 5.15. * p = 0.01;
** p < 0.01; **** p < 0.001, n = 3.
3.4. Alteration of Neurite Outgrowth during In Vitro MPS1-H Neuronal Differentiation
Thereafter, we investigated potential pathological effect resulting from IDUAα deficiency during
neuronal maturation. Thus, immature rescued and MPS1-H iPSCs-derived NSCs were further
differentiated toward neuronal lineage during three more weeks in monolayer, by removing the
proliferative growth factors FGF2 and EGF, involved in NSCs stemness. During the 3 weeks
differentiation process, we observed a striking difference in the neurite outgrowth of MPS1-H
affected neurons compared to rescued neurons. Unlike classic neuronal differentiations or rMPS1-H
neuronal cultures, neurites of MPS1-H neurons, stained by the Microtubule-associated protein 2
(MAP2), tended to group together to form bundles and did not spread their neurites over all the
culture dish (Figure 4A–C). MPS1-H NSCs cultures showed lesser MAP2 stained area compared to
rescued conditions. In order to assess this difference in distribution of neurons, we first counted the
number of nuclei (Figure 4D) and normalized the MAP2 positive area to this number (Figure 4E).
Thus, an automatic analysis determined the neurite surface per nuclei of each MPS1-H clones: S1:
36.82 ± 1.36 µm2/nucleus; S2: 30.64 ± 5.2 µm2/nucleus; S4: 46.34 ± 4.1 µm2/nucleus; and rMPS1-H
clones: S1R: 46.8 ± 4.93 µm2/nucleus; S2R: 50.69 ± 8.08 µm2/nucleus; S4R: 68.78 ± 30.2 µm2/nucleus.
No major variation of nuclei number was observed at the end of NSCs differentiation.
This confirmed that MPS1-H and rMPS1-H cells have a similar proliferation rate during
neuronal differentiation.
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4′
Figure 4. Analyze of neurite outgrowth of MPS1-H iPSCs-derived NSCs and rescued counterparts after
3 weeks of differentiation. (A,B) Defective neurite outgrowth of MPS1-H iPSCs-derived NSCs compared
to rescued NSCs is revealed by MAP2 staining at low magnification (scale bars = 50 µm) and (C) high
magnification (scale bars = 15 µm) after 3 weeks of differentiation. Nuclei was counterstained with
Hoechst. (D) Automatic analysis quantified the number of nuclei and (E) determined the MAP2-positive
neurite surface per nuclei in the different clones. Data are shown as mean ± SEM and were analyzed by
independent samples t-test. * p < 0.01.
3.5. Transcriptome Analysis of MPS1-H Affected and Rescued iPSCs-Derived Neurospheres
In order to identify signaling pathways that may explain some of the neurological dysfunctions
observed in MPS1-H, we performed a transcriptomic analysis with RNA-seq on 3 weeks-old
neurospheres derived from both rescued and affected MPS1-H iPSCs. The number of genes
expressed was 14′839. We found 173 downregulated and 167 upregulated genes in the MPS1-H
neurospheres compared to the rescued ones. These genes represented 23 biological processes
from KEGG. Key differences were objectivized in association with TGF beta pathway (six genes;
p = 1.38 × 10−6), focal adhesion pathway (four genes; p = 0.0106), PI3K-akt signaling pathways (five
genes, p = 0.0172), Hippo signaling pathway (four genes; p = 0.0043), RAP1 pathway (four genes
p = 0.0127), extracellular matrix (ECM) interaction pathway (two genes; p = 0.049), calcium signaling
pathway (three genes; p = 0.044) (Figure 5A). The 20 most down-regulated and the 20 most upregulated
genes are shown in Table 1.
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Figure 5. RNA-seq analyzes of 3-week-old MPS1-H and rMPS1-H neurospheres. (A) Heatmap displayed
of differential expressed genes in MPS I rescued (left) and MPS1-H affected clones. Gene expression
is represented through Z-score values and according to the brightness of the color code. The red
line separates the rescued MPS1-H cluster (left-half ) from the diseased MPS1-H cluster (right-half ).
The red arrow marks the IDUA expression. (B) Network analysis of differentially expressed genes
highlighting four clusters of interacting protein. Each node represents a proteins and edges represent
interactions between proteins. Turquoise colored lines represent interactions coming from curated
databases; magenta colored lines represent known interactions that have been experimentally defined;
other colors are representing predicted interactions, such as gene co-occurrence (blue), gene fusions
(red), gene neighborhood (green). The homeobox cluster, stemness cluster, surface cell receptors cluster,
neuro embryologic cluster are highlighted. This plot was generated with the string database v.11.0
(http://string-db.org).
To further highlight connections between the differentially expressed genes, we performed string
analysis. This analysis allowed the identification of four main interaction clusters: the homeobox
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cluster, the stemness cluster, the cell surface receptors cluster (made up mainly of receptor-tyrosine
kinases) and the neuro-embryologic cluster (Figure 5B).
Table 1. RNA-seq of MPS1-H iPSCs derived neurospheres normalized on rescued neurospheres.
Upregulated Genes Downregulated Genes
Gene Name Log FC False Discovery Rate (FDR) Gene Name Log FC False Discovery Rate (FDR)
HOXA3 8.498 0.014 LINC01405 −5.762 0.038
HOXA7 7.852 0.032 ZFP42 −5.879 0.061
HOXB9 7.789 0.030 ACOXL −6.305 0.039
HOXA5 7.530 0.032 JAKMIP2-AS1 −6.335 0.034
EDAR 7.514 0.036 ZSCAN10 −6.423 0.034
SOST 7.251 0.058 PRDM14 −6.602 0.034
HOXC9 7.192 0.030 LINC00428 −6.659 0.034
HOXC6 6.280 0.039 VRTN −6.694 0.039
HOXA6 6.054 0.046 DPPA3 −6.734 0.032
GDF7 5.721 0.079 FOXH1 −6.858 0.032
HOXB3 5.710 0.046 LINC00678 −7.005 0.032
SLC6A5 5.664 0.042 NODAL −7.012 0.039
HOXB5 5.618 0.034 TDGF1 −7.073 0.036
PRSS56 5.535 0.039 HHLA1 −7.299 0.027
HOXB4 5.501 0.046 LINC01108 −7.349 0.030
HOXB8 5.455 0.046 TRIML2 −7.479 0.030
HOXB7 5.296 0.036 SCGB3A2 −7.745 0.030
HOXC4 5.226 0.039 LOC101929194 −7.835 0.078
ATOH1 5.170 0.085 POU5F1 −7.861 0.032
HOXB1 5.048 0.042 ESRG −8.122 0.032
Values in the table refer to the comparison of neurospheres derived from diseased vs. rescued MPS1-H iPSCs.
The term “upregulated genes” refers to an expression that is higher in diseased vs. rescued neutrospheres.
4. Discussion
Disease models are crucial tools to identify and appreciate pathological mechanisms responsible
to the development of a disease [37]. Therefore, it is essential to have a relevant study model which
must reproduce the pathological features of the disease to be able to design novel therapeutic strategies.
Despite the possibility to obtain primary cells from patients affected from various inherited diseases,
in vitro disease modeling was highly limited during the past due to the difficulties to maintaining
these cells in culture. Cardiovascular or neurological diseases modelling was even more challenging
due to the additional limitation linked to the access to patient’s tissues. The discovery and the
isolation of human embryonic stem cells (hESCs) [38] in 1998, first allowed to lift a part of these
constraints. Indeed, their ability to undergo unlimited self-renewal in culture followed by their
differentiation into multiple cell types of the body [39–42] allowed the establishment of models for
many diseases, including muscular or neurological diseases [43–47]. However, the possibility to
model any disorder, including the one not tested during preimplantation genetic diagnosis (PGD),
such as neurodegenerative diseases [48–52] was made possible by the recent discovery of iPSCs by
Yamanaka [53], allowing the conversion of somatic cells into pluripotent stem cells [54,55].
In this study, we took advantage of the capacity of differentiation of an iPSCs line, previously
derived from a MPS1-H child [30], to investigate the effect of IDUAα deficiency during neural
development which could explained some neural disorders observed on MPS1-H patients. Since RNA
sequencing was one of the mainstays of our strategy, we needed a control iPSCs line presenting the
most similar genetic background to our MPS1-H iPSC line to identify gene variations resulting from
the disease-associated mutation rather than genetic background noise [31,56]. As we did not dispose to
an iPSCs control line from a parent or a close relative, we generated an isogenic line by rescuing IDUA
expression in our MPS1-H iPSCs line by a lentivector [32]. Although recent advances in genome editing
technology would have corrected the mutation without insertion of new DNA sequence, or even
producing an isogenic MPS1-H line by introducing a specific mutation into one of our control iPSCs
line [57,58], this technology remains challenging for the non-expert operators. Nevertheless, similarly
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to the work of Tolar et al., [59] the self-renewal and the differentiation potential of our isogenic control
iPSCs clones was not altered by the integration of the lentivector. Moreover, our results reported a
similar level of IDUAα activity in rescued cells compared to control ones (Figure 1).
Differentiation of MPS1-H affected iPSCs clones into neuronal cells revealed both migration
defects and alteration of neurite outgrowth compared to their three rescued counterparts. Our results
revealed a similar cell proliferation between MPS1-H iPSCs and rMPS1-H iPSCs during neuronal
differentiation, the accumulation of GAGs, resulting for IDUAα deficiency, remains the most evident
hypothesis that could explain these defects as it was highlighted in MPS3 also known as Sanfilippo
syndrome [18–20]. Indeed, CS and HS proteoglycans which are the main components of the cell surface
and ECM in the brain [60], are known for their binding properties and are consequently involved
in multiple biological pathways [61], including cell migration, cell adhesion and cell polarization
processes [62,63]. By binding axon guidance molecules such as ephrin, netrins, semaphorins and Slit
families, they must highly disrupt cell migration and neurite outgrowth [64] during brain development.
Moreover, many studies have highlighted the crucial role of ECM in neurodevelopment and have even
linked the appearance of neurodegenerative disorders to its disruption [65].
A striking result of our study is the magnitude and the coherence of the changes in gene expression.
Basically, changes in gene expression concerned 23 biological processes and were identified as four
clusters by string analysis. These changes make sense in the context of the cellular alterations
observed in our study, as well as the neuropathological features described in MPS1-H patients. Indeed,
focal adhesion pathway, RAP1 pathway [66] and ECM interaction pathway point towards cell motility
and the migration defect identified above since the alteration in expression of the Hippo pathway [67]
and homeobox genes and neuro-embryologic genes point toward the neuroanatomical defects.
Taken together our results demonstrate a defect in migration of neural precursor cells, as well as
massive changes of gene expression in neuronal cells derived from MPS1-H iPSCs. The relationship
between migration defect and changes in gene expression are most likely bidirectional: altered adhesion
and ECM gene expression is likely to precede an alteration of cell migration, but impairment of cell
migration can also lead to altered gene expression. Further studies will be necessary to define the
contribution of these individual factors to MPS1-H neurological disease. We are confident that our
study provides a strong framework to advance for such an endeavor.
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Wilkinson, F.L.; Bigger, B.W. Hyperactive behaviour in the mouse model of mucopolysaccharidosis IIIB in
the open field and home cage environments. Genes Brain Behav. 2011, 10, 673–682. [CrossRef]
29. Canal, M.M.; Wilkinson, F.L.; Cooper, J.D.; Wraith, J.E.; Wynn, R.; Bigger, B.W. Circadian rhythm and
suprachiasmatic nucleus alterations in the mouse model of mucopolysaccharidosis IIIB. Behav. Brain Res.
2010, 209, 212–220. [CrossRef]
30. Lito, S.; Burda, P.; Baumgartner, M.; Sloan-Béna, F.; Táncos, Z.; Kobolák, J.; Dinnyés, A.; Krause, K.-H.;
Marteyn, A. Generation of human induced pluripotent stem cell line UNIGEi001-A from a 2-years old patient
with Mucopolysaccharidosis type IH disease. Stem Cell Res. 2019, 41, 101604. [CrossRef]
31. Rouhani, F.; Kumasaka, N.; De Brito, M.C.; Bradley, A.; Vallier, L.; Gaffney, D. Genetic Background Drives
Transcriptional Variation in Human Induced Pluripotent Stem Cells. PLoS Genet. 2014, 10, e1004432.
[CrossRef]
32. Salmon, P. Generation of Human Cell Lines Using Lentiviral-Mediated Genetic Engineering. Methods Mol. Biol.
2012, 945, 417–448. [CrossRef]
33. Minami, R.; Watanabe, Y.; Kudoh, T.; Oyanagi, K.; Nakao, T. Fluorometric measurement of
alpha-L-iduronidase activity using 4-methylumbelliferyl-alpha-L-iduronide. Tohoku J. Exp. Med. 1980, 130,
381–384. [CrossRef] [PubMed]
34. Chambers, S.M.; Fasano, C.A.; Papapetrou, E.P.; Tomishima, M.; Sadelain, M.; Studer, L. Highly efficient
neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 2009, 27,
275–280. [CrossRef] [PubMed]
35. Robinson, M.D.; McCarthy, D.J.; Smyth, G.K. edgeR: A Bioconductor package for differential expression
analysis of digital gene expression data. Bioinformatics 2010, 26, 139–140. [CrossRef] [PubMed]
36. Rahimi-Balaei, M.; Bergen, H.; Kong, J.; Marzban, H. Neuronal Migration During Development of the
Cerebellum. Front. Cell. Neurosci. 2018, 12, 484. [CrossRef]
37. Sterneckert, J.L.; Reinhardt, P.; Schöler, H.R. Investigating human disease using stem cell models.
Nat. Rev. Genet. 2014, 15, 625–639. [CrossRef]
38. Thomson, J.A.; Itskovitz-Eldor, J.; Shapiro, S.S.; Waknitz, M.A.; Swiergiel, J.J.; Marshall, V.S.; Jones, J.M.
Embryonic Stem Cell Lines Derived from Human Blastocysts. Science 1998, 282, 1145–1147. [CrossRef]
39. Barberi, T.; Klivenyi, P.; Calingasan, N.Y.; Lee, H.; Kawamata, H.; Loonam, K.; Perrier, A.L.; Bruses, J.;
Rubio, M.E.; Topf, N.; et al. Neural subtype specification of fertilization and nuclear transfer embryonic stem
cells and application in parkinsonian mice. Nat. Biotechnol. 2003, 21, 1200–1207. [CrossRef]
40. Harding, S.E.; Ali, N.N.; Brito-Martins, M.; Gorelik, J. The human embryonic stem cell-derived cardiomyocyte
as a pharmacological model. Pharmacol. Ther. 2007, 113, 341–353. [CrossRef]
41. Lavon, N.; Yanuka, O.; Benvenisty, N. Differentiation and isolation of hepatic-like cells from human embryonic
stem cells. Differentiation 2004, 72, 230–238. [CrossRef]
42. Perrier, A.L.; Tabar, V.; Barberi, T.; Rubio, M.E.; Bruses, J.; Topf, N.; Harrison, N.L.; Studer, L. Derivation
of midbrain dopamine neurons from human embryonic stem cells. Proc. Natl. Acad. Sci. USA 2004, 101,
12543–12548. [CrossRef]
43. Gauthier, M.; Marteyn, A.; Denis, J.A.; Cailleret, M.; Giraud-Triboult, K.; Aubert, S.; Lecuyer, C.; Marie, J.;
Furling, D.; Vernet, R.; et al. A defective Krab-domain zinc-finger transcription factor contributes to altered
myogenesis in myotonic dystrophy type 1. Hum. Mol. Genet. 2013, 22, 5188–5198. [CrossRef] [PubMed]
Cells 2020, 9, 2593 15 of 16
44. Mateizel, I.; De Temmerman, N.; Ullmann, U.; Cauffman, G.; Sermon, K.; Van De Velde, H.; De Rycke, M.;
Degreef, E.; Devroey, P.; Liebaers, I.; et al. Derivation of human embryonic stem cell lines from embryos
obtained after IVF and after PGD for monogenic disorders. Hum. Reprod. 2005, 21, 503–511. [CrossRef]
[PubMed]
45. Urbach, A.; Schuldiner, M.; Benvenisty, N. Modeling for Lesch-Nyhan Disease by Gene Targeting in Human
Embryonic Stem Cells. Stem Cells 2004, 22, 635–641. [CrossRef]
46. Verlinsky, Y.; Strelchenko, N.; Kukharenko, V.; Rechitsky, S.; Galat, V.; Kuliev, A. Human embryonic stem cell
lines with genetic disorders. Reprod. Biomed. Online 2005, 10, 105–110. [CrossRef]
47. Evans, T. Embryonic stem cells as a model for cardiac development and disease. Drug Discov. Today Dis. Model.
2008, 5, 147–155. [CrossRef] [PubMed]
48. Ebert, A.D.; Yu, J.; Rose, F.F., Jr.; Mattis, V.B.; Lorson, C.L.; Thomson, J.A.; Svendsen, C.N. Induced pluripotent
stem cells from a spinal muscular atrophy patient. Nature 2009, 457, 277–280. [CrossRef] [PubMed]
49. Park, I.H.; Arora, N.; Huo, H.; Maherali, N.; Ahfeldt, T.; Shimamura, A.; Lensch, M.W.; Cowan, C.;
Hechedlinger, K.; Daley, G.Q. Disease-specific induced pluripotent stem cells. Cell 2008, 134, 877–886.
[CrossRef] [PubMed]
50. Chestkov, I.V.; Vasilieva, E.A.; Illarioshkin, S.N.; Lagarkova, M.A.; Kiselev, S.L. Patient-Specific Induced
Pluripotent Stem Cells for SOD1-Associated Amyotrophic Lateral Sclerosis Pathogenesis Studies. Acta Nat.
2014, 6, 54–60. [CrossRef]
51. Mungenast, A.E.; Siegert, S.; Tsai, L.-H. Modeling Alzheimer’s disease with human induced pluripotent
stem (iPS) cells. Mol. Cell. Neurosci. 2016, 73, 13–31. [CrossRef]
52. Nekrasov, E.D.; Vigont, V.A.; Klyushnikov, S.A.; Lebedeva, O.S.; Vassina, E.M.; Bogomazova, A.N.;
Chestkov, I.V.; Semashko, T.A.; Kiseleva, E.; Suldina, L.A.; et al. Manifestation of Huntington’s disease
pathology in human induced pluripotent stem cell-derived neurons. Mol. Neurodegener. 2016, 11, 27.
[CrossRef]
53. Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of
pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131, 861–872. [CrossRef]
[PubMed]
54. Yoshida, Y.; Yamanaka, S. Recent Stem Cell Advances: Induced Pluripotent Stem Cells for Disease Modeling
and Stem Cell-Based Regeneration. Circulation 2010, 122, 80–87. [CrossRef] [PubMed]
55. Unternaehrer, J.J.; Daley, G.Q. Induced pluripotent stem cells for modelling human diseases. Philos. Trans. R.
Soc. B Biol. Sci. 2011, 366, 2274–2285. [CrossRef] [PubMed]
56. Musunuru, K. Genome editing of human pluripotent stem cells to generate human cellular disease models.
Dis. Model. Mech. 2013, 6, 896–904. [CrossRef]
57. Ding, Q.; Lee, Y.-K.; Schaefer, E.A.K.; Peters, D.T.; Veres, A.; Kim, K.; Kuperwasser, N.; Motola, D.L.;
Meissner, T.B.; Hendriks, W.T.; et al. A TALEN Genome-Editing System for Generating Human Stem
Cell-Based Disease Models. Cell Stem Cell 2013, 12, 238–251. [CrossRef]
58. Horii, T.; Tamura, D.; Morita, S.; Kimura, M.; Hatada, I. Generation of an ICF Syndrome Model by Efficient
Genome Editing of Human Induced Pluripotent Stem Cells Using the CRISPR System. Int. J. Mol. Sci. 2013,
14, 19774–19781. [CrossRef]
59. Tolar, J.; Park, I.-H.; Xia, L.; Lees, C.J.; Peacock, B.; Webber, B.; McElmurry, R.T.; Eide, C.R.; Orchard, P.J.;
Kyba, M.; et al. Hematopoietic differentiation of induced pluripotent stem cells from patients with
mucopolysaccharidosis type I (Hurler syndrome). Blood 2011, 117, 839–847. [CrossRef]
60. Maeda, N.; Ishii, M.; Nishimura, K.; Kamimura, K. Functions of Chondroitin Sulfate and Heparan Sulfate in
the Developing Brain. Neurochem. Res. 2010, 36, 1228–1240. [CrossRef]
61. Sarrazin, S.; Lamanna, W.C.; Esko, J.D. Heparan Sulfate Proteoglycans. Cold Spring Harb. Perspect. Biol. 2011,
3, a004952. [CrossRef]
62. De Wit, J.; Verhaagen, J. Proteoglycans as Modulators of Axon Guidance Cue Function. Biol. Mammary Gland
2007, 600, 73–89. [CrossRef]
63. Xian, X.; Gopal, S.; Couchman, J.R. Syndecans as receptors and organizers of the extracellular matrix.
Cell Tissue Res. 2010, 339, 31–46. [CrossRef] [PubMed]
64. Marteyn, A.; Maury, Y.; Gauthier, M.M.; Lecuyer, C.; Vernet, R.; Denis, J.A.; Pietu, G.; Peschanski, M.;
Martinat, C. Mutant Human Embryonic Stem Cells Reveal Neurite and Synapse Formation Defects in Type
1 Myotonic Dystrophy. Cell Stem Cell 2011, 8, 434–444. [CrossRef] [PubMed]
Cells 2020, 9, 2593 16 of 16
65. Bonneh-Barkay, D.; Wiley, C.A. Brain Extracellular Matrix in Neurodegeneration. Brain Pathol. 2009, 19,
573–585. [CrossRef] [PubMed]
66. Bos, J.L.; De Bruyn, K.; Enserink, J.; Kuiperij, B.; Rangarajan, S.; Rehmann, H.; Riedl, J.; De Rooij, J.; Van
Mansfeld, F.; Zwartkruis, F. The role of Rap1 in integrin-mediated cell adhesion. Biochem. Soc. Trans. 2003,
31, 83–86. [CrossRef] [PubMed]
67. Yu, F.-X.; Zhao, B.; Guan, K.L. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell
2015, 163, 811–828. [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
affiliations.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
